The Portfolio returned 4.36% gross, outperforming the Russell Midcap Growth Index return of 2.78%. Read the full report to ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback